<DOC>
	<DOCNO>NCT00689260</DOCNO>
	<brief_summary>This study help determine whether injection log recombinant human growth hormone ( rhGH ) delivery device improve subject ' adherence injection schedule . Adherence compare group subject aware injection log easypod™ rhGH delivery device group subject aware easypod™ injection log . It study hypothesis subject non-adherence rate different aware injection log capability versus unaware injection log capability . Subject perception also evaluate compare ease convenience use subject preference easypod™ compare two rhGH pen injection device .</brief_summary>
	<brief_title>Easypod United States User Trial</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<criteria>Be male female 10 18 year age , inclusive , open epiphysis Have GH deficiency diagnose treat pediatric endocrinologist least 6 month Be undergo rhGH treatment via selfinjection use Lilly Humatrope® Pfizer Genotropin® pen injection device least 6 month Be willing able comply protocol duration trial Have access Internet Be able read , speak understand English If female childbearing potential , negative urine pregnancy test Screening use acceptable form birth control trial , include abstinence , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide Known allergy hypersensitivity rhGH prescribe diluent ( 0.3 % metacresol click.easy® cartridge ) Severe illness previous 6 month Active malignancy ( except nonmelanomatous skin malignancy ) Diabetes mellitus ( type I II ) Pregnancy lactation Any medical condition , opinion Investigator , would jeopardize subject 's safety follow exposure investigational device Participation investigational study duration participation trial</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>